Duloxetine Boehringer Ingelheim

RSS

Withdrawn

This medicine's authorisation has been withdrawn

duloxetine
MedicineHumanWithdrawn

Maltese is available via eTranslation, the European Commission's machine translation service.

Translate to Maltese | Important information about machine translation

  • Application under evaluation
  • CHMP opinion
  • European Commission decision

Overview

On the 8th October 2008 the European Commission issued a marketing authorisation valid throughout the European Union for the medicinal product Duloxetine Boehringer Ingelheim, duloxetine, which had been approved for the treatment of diabetic peripheral neuropathic pain in adults. The marketing authorisation holder (MAH) responsible for Duloxetine Boehringer Ingelheim was Boehringer Ingelheim International GmbH. 

The European Commission was notified by a letter dated 12 April 2010 of the MAH’s decision to voluntarily withdraw the marketing authorisation as of the Commission Decision date for Duloxetine Boehringer Ingelheim for commercial reasons. 

Duloxetine Boehringer Ingelheim was not marketed in any European country. On 26th May 2010 the European Commission issued a decision to withdraw the marketing authorisation for Duloxetine Boehringer Ingelheim. 

Pursuant to this decision the European Public Assessment Report for Duloxetine Boehringer Ingelheim is updated to reflect that the marketing authorisation is no longer valid.

български (BG) (452.19 KB - PDF)

Ara

español (ES) (275.13 KB - PDF)

Ara

čeština (CS) (421.81 KB - PDF)

Ara

dansk (DA) (272.92 KB - PDF)

Ara

Deutsch (DE) (275.83 KB - PDF)

Ara

eesti (ET) (492.34 KB - PDF)

Ara

ελληνικά (EL) (451.96 KB - PDF)

Ara

français (FR) (274.9 KB - PDF)

Ara

italiano (IT) (495.52 KB - PDF)

Ara

latviešu (LV) (427.77 KB - PDF)

Ara

lietuvių (LT) (393.88 KB - PDF)

Ara

magyar (HU) (409.78 KB - PDF)

Ara

Malti (MT) (420.82 KB - PDF)

Ara

Nederlands (NL) (273.77 KB - PDF)

Ara

polski (PL) (431.59 KB - PDF)

Ara

português (PT) (274.47 KB - PDF)

Ara

română (RO) (387.33 KB - PDF)

Ara

slovenčina (SK) (415.13 KB - PDF)

Ara

slovenščina (SL) (652.91 KB - PDF)

Ara

suomi (FI) (273.51 KB - PDF)

Ara

svenska (SV) (272.73 KB - PDF)

Ara

Product information

български (BG) (967.25 KB - PDF)

Ara

español (ES) (583.9 KB - PDF)

Ara

čeština (CS) (541.09 KB - PDF)

Ara

dansk (DA) (578.77 KB - PDF)

Ara

Deutsch (DE) (588.98 KB - PDF)

Ara

eesti (ET) (581.38 KB - PDF)

Ara

ελληνικά (EL) (997.7 KB - PDF)

Ara

français (FR) (609.98 KB - PDF)

Ara

italiano (IT) (569.07 KB - PDF)

Ara

latviešu (LV) (837.09 KB - PDF)

Ara

lietuvių (LT) (771.49 KB - PDF)

Ara

magyar (HU) (705.83 KB - PDF)

Ara

Malti (MT) (780.04 KB - PDF)

Ara

Nederlands (NL) (599.55 KB - PDF)

Ara

polski (PL) (830.47 KB - PDF)

Ara

português (PT) (599.22 KB - PDF)

Ara

română (RO) (743.43 KB - PDF)

Ara

slovenčina (SK) (570.7 KB - PDF)

Ara

slovenščina (SL) (696.09 KB - PDF)

Ara

suomi (FI) (608.7 KB - PDF)

Ara

svenska (SV) (560.49 KB - PDF)

Ara
Latest procedure affecting product information:P46/008
07/12/2009
icon globe

This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.

 

Product information documents contain:

  • summary of product characteristics (annex I);
  • manufacturing authorisation holder responsible for batch release (annex IIA);
  • conditions of the marketing authorisation (annex IIB);
  • labelling (annex IIIA);
  • package leaflet (annex IIIB).

български (BG) (322.9 KB - PDF)

Ara

español (ES) (223.34 KB - PDF)

Ara

čeština (CS) (273.91 KB - PDF)

Ara

dansk (DA) (224.46 KB - PDF)

Ara

Deutsch (DE) (223.13 KB - PDF)

Ara

eesti (ET) (223.49 KB - PDF)

Ara

ελληνικά (EL) (316.36 KB - PDF)

Ara

français (FR) (223.13 KB - PDF)

Ara

italiano (IT) (223.12 KB - PDF)

Ara

latviešu (LV) (316.7 KB - PDF)

Ara

lietuvių (LT) (292.53 KB - PDF)

Ara

magyar (HU) (274.52 KB - PDF)

Ara

Malti (MT) (315.61 KB - PDF)

Ara

Nederlands (NL) (223.77 KB - PDF)

Ara

polski (PL) (315.91 KB - PDF)

Ara

português (PT) (223.33 KB - PDF)

Ara

română (RO) (288.79 KB - PDF)

Ara

slovenčina (SK) (273.54 KB - PDF)

Ara

slovenščina (SL) (247.19 KB - PDF)

Ara

suomi (FI) (223.23 KB - PDF)

Ara

svenska (SV) (229.64 KB - PDF)

Ara

Product details

Name of medicine
Duloxetine Boehringer Ingelheim
Active substance
duloxetine
International non-proprietary name (INN) or common name
duloxetine
Therapeutic area (MeSH)
Diabetic Neuropathies
Anatomical therapeutic chemical (ATC) code
N06AX21

Pharmacotherapeutic group

Psychoanaleptics

Therapeutic indication

Treatment of diabetic peripheral neuropathic pain in adults.

Authorisation details

EMA product number
EMEA/H/C/001007
Marketing authorisation holder
Boehringer Ingelheim International GmbH

Binger Str 173
D-55216 Ingelheim am Rhein
Germany

Marketing authorisation issued
08/10/2008
Withdrawal of marketing authorisation
26/05/2010
Revision
2

Assessment history

This page was last updated on

Share this page